Skip to: [Content] [Navigation]

Natus Medical Receives Medical Design Excellence Award for the Olympic Cool-Cap

San Carlos, CA (April 10, 2007) - Natus Medical Incorporated (NASDAQ:BABY) today announced that it was awarded a 2007 Medical Design Excellence Award for its Olympic Cool-Cap(R) head-cooling product for newborn brain injury. The award will be presented to Natus at a ceremony to be held June 13, 2007 in New York City.

Sponsored by Medical Device & Diagnostic Industry magazine, the Medical Design Excellence Awards competition is the only program to exclusively recognize companies and individuals for their advances and contributions in medical product design. The Olympic Cool-Cap and other medical devices were evaluated for innovative use of materials, ability of product development teams to overcome design and engineering challenges, user-related functions that improve healthcare delivery, and features that provide enhanced benefits to the patient. Entries were evaluated by a panel of judges with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.

The Olympic Cool-Cap is used in conjunction with the Company's Olympic CFM 6000 Cerebral Function Monitor, which aids in identifying neurological abnormalities such as hypoxic ischemic encephalopathy ("HIE"), a condition that can result from an interruption of blood flow and oxygen supply during labor and delivery.

"We are honored to receive this very prestigious award for the second time in three years, as it validates our successful R&D efforts," stated Jim Hawkins, President and Chief Executive Officer of Natus. "Through extensive customer evaluations and design feedback culminating in a landmark HIE clinical trial, the Research & Development team at our Olympic Medical division designed an important and unique medical device that will benefit these severely injured newborns."

"Once again Natus is leading the market by providing customers with products that deliver significant benefits," added Hawkins. "We were clearly a leader in the development of newborn hearing screening as a standard of care, and we expect to leverage that experience as we now look to make routine brain monitoring of newborns and head-cooling for the treatment of HIE new standards of care."

For more information on the Olympic Cool-Cap, visit the Natus website at www.natus.com. To obtain additional information on the Medical Device Excellence Award, visit www.MDEAwards.com.

About Natus Medical Incorporated
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.

Additional information about Natus Medical can be found at www.natus.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include, but are not limited to, statements regarding the functionality of the Olympic CFM 6000 Cerebral Function Monitor and Olympic Cool-Cap products, as well as the acceptance of brain monitoring in newborns and head-cooling for the treatment of HIE as standards of care. These statements relate to future events or Natus' future financial performance or results, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, and risks associated with bringing new products to market and integrating acquired businesses. Natus disclaims any obligation to update information contained in any forward-looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

CONTACT:

Natus Medical Incorporated
Steven J. Murphy, Chief Financial Officer, 650-802-0400
InvestorRelations@Natus.com